KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read More
Tim Lowery serves as interim CEO for KBI Biopharma and Selexis. Tim joined JSR in 1996. Since then, he has supported JSR in several capacities, including as CEO of MBLI, a JSR Life Sciences company. Tim was instrumental in establishing JSR’s life sciences business, spearheading the company’s M&A activities, and global expansion of life science operations.
As President, he is responsible for the development and integration of global strategies among all the JSR Life Sciences companies, which include Crown Bioscience, KBI Biopharma, Inc., MBL and Selexis SA.
Tim holds a bachelor's degree in Mechanical Engineering from North Carolina State University and an MBA from Duke University’s Fuqua School of Business.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2023 Selexis SA. All Rights Reserved.